| Literature DB >> 31578863 |
Hope Adamson, Modupe O Ajayi, Emma Campbell, Erika Brachi, Christian Tiede, Anna A Tang, Thomas L Adams, Robert Ford1, Alex Davidson1, Matt Johnson1, Michael J McPherson, Darren C Tomlinson, Lars J C Jeuken.
Abstract
Robust technology is required to underpin rapid point-of-care and in-field diagnostics to improve timely decision making across broad sectors. An attractive strategy combines target recognition and signal generating elements into an "active" enzyme-switch that directly transduces target-binding into a signal. However, approaches that are broadly applicable to diverse targets remain elusive. Here, an enzyme-inhibitor switch sensor was developed by insertion of non-immunoglobulin Affimer binding proteins, between TEM1-β-lactamase and its inhibitor protein, such that target binding disrupts the enzyme-inhibitor complex. Design principles for a successful switch architecture are illustrated by the rapid (min), simple (wash-free), and sensitive (pM) quantification of multimeric target analytes in biological samples (serum, plasma, leaf extracts), across three application areas. A therapeutic antibody (Herceptin), protein biomarker (human C-reactive protein), and plant virus (cow pea mosaic virus) were targeted, demonstrating assays for therapeutic drug monitoring, health diagnostics, and plant pathogen detection, respectively. Batch-to-batch reproducibility, shelf-life stability, and consistency with validated enzyme-linked immunosorbent assay analysis confirm that the principle of an Affimer-enzyme-inhibitor switch provides a platform for point-of-care and in-field diagnostics.Entities:
Keywords: Affimers; biosensor; homogenous assay; in-field; point-of-care; protein engineering; protein switch; wash-free diagnostics
Mesh:
Substances:
Year: 2019 PMID: 31578863 DOI: 10.1021/acssensors.9b01574
Source DB: PubMed Journal: ACS Sens ISSN: 2379-3694 Impact factor: 7.711